A study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of NSCLC

Recently, HER2 amplification was recognised as a mechanism of acquired resistance to EGFR-TKI that occurs in a subset of tumours lacking the acquired, somatic resistance EGFRT790M mutation. This novel molecular insight in large sample of NSCLC cases was presented by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine, Omaha, USA and Director of Oncologic Pathology at Caris Life Sciences International at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), held 9-11 May, 2013 in Lugano, Switzerland. Read more here.